CSPC Pharmaceutical (HKG:1093) said a phase 2/3 trial of its KN026 anti-cancer drug met the primary endpoint of progression-free survival, according to a Wednesday filing with the Hong Kong bourse.
The drug, which treats patients with human epidermal growth factor receptor 2-positive locally advanced, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma, is developed by Shanghai JMT-Bio Technology and Jiangsu Alphamab Oncology.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。